More News! 9 Nov 2022 PrecisionLife supports Sosei Heptares to treat chronic diseases in more personalized way PrecisionLife, developers of precision medicine for chronic diseases, will be supporting biopharmaceutical group, Sosei Heptares, to develop better, more personalized treatment options. Specifically, global techbio PrecisionLife, will assess the precision medicine potential of a neuroscience target nominated by Sosei Heptares, that specializes in structure-based drug design targeting G protein-coupled receptors (GPCRs). Sosei Heptares will leverage […] November 9, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2022 AI program yields multiple novel RSV drug targets Poolbeg Pharma says it has made a breakthrough in its Artificial Intelligence (AI) program with partner OneThree Biotech, Inc. through the discovery of novel drug targets for the treatment of respiratory syncytial virus (RSV). Following the completion of the build and optimization of a tailored AI model in June 2022, the OneThree team, using its […] November 8, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2022 Hormone discovery could predict long term health of men Researchers have discovered the vital role of INSL3, a hormone that develops in men during puberty, which provides an early prediction of whether they could develop certain diseases in later life. Scientists from the University of Nottingham in the U.K. have discovered that the novel insulin-like peptide hormone, INSL3, is consistent over long periods of […] November 8, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2022 Scancell in-licenses Vaccitech’s SNAPvax tech for cancer study Scancell Holdings plc, a developer of immunotherapies, today (November 7) announced it has in-licensed the SNAPvax technology from Vaccitech plc, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapies and vaccines. The agreement will allow Scancell to formulate and manufacture Modi-2, with the aim of initiating a phase 1 clinical study […] November 7, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2022 Proteins identified by FunSel and developed by Forcefield can preserve heart function Forcefield Therapeutics, has presented positive preclinical data on three proteins identified by it FunSel platform that have the potential to preserve heart function following a heart attack. The company that works with therapeutics to protect heart function by arresting the loss of cardiomyocytes following myocardial infarction infarction. The paper, Novel Recombinant Cardioprotective Factors Against Myocardial […] November 7, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2022 EMPA-KIDNEY trial meets primary endpoint in trial for drug to treat chronic kidney disease A phase 3 clinical trial, EMPA-KIDNEY, met its primary endpoint showing a significant kidney and cardiovascular benefit for adults living with chronic kidney disease (CKD). When treated with Jardiance (empagliflozin), the risk of kidney disease progression or cardiovascular death was significantly reduced by 28% versus placebo. The results were announced today during the American Society of […] November 4, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 4 Nov 2022 Alimentiv and Summit collaborate to tackle liver disease NASH Drug development programs will be driven forward by a collaboration between Alimentiv Inc. and Summit Clinical Research, in a bid to tackle non-alcoholic steatohepatitis (NASH). They announced a strategic alliance to tackle the now growing global epidemic with no approved treatments. It says that current challenges include optimizing and end-point assessment, minimizing screen failures and […] November 4, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 3 Nov 2022 New method to treat diabetic foot ulcers revealed by Biocomposites Ltd Diabetic foot infection costs the UK’s NHS around £900 million ($990 million) a year, bringing severe misery to patients. Usually, systemic antibiotics are routinely given to those with diabetes who are susceptible to infected foot ulcers. Unfortunately, effective treatment can be disrupted by complications by using this treatment due to allergic reactions, antibiotic-resistant organisms, the […] November 3, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 3 Nov 2022 Virax Biolabs introduces flu, Covid-19 and RSV rapid test kits Rapid test kits that can accurately identify infections related to respiratory syncytial virus (RSV), influenza and Covid-19 can deliver results in 15 minutes. UK-based Virax Biolabs, a biotech company focused on the prevention, detection and diagnosis of viral diseases announced today (November 3) the distribution of a tripe virus antigen rapid test kit has been […] November 3, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2022 CV6 Therapeutics raises $9.2M to test cancer drug CV6 Therapeutics has secured $9.2m to progress its lead oncology asset, CV6-168, into a first-in-human phase 1a clinical trial and perform further scientific development work. CV6 Therapeutics is a drug development biotechnology company specializing in innovative small molecule therapeutics for cancer and inflammatory diseases. Investors participating in the financing include QUBIS, the commercialization arm of […] November 2, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2022 Pancreatic cancer could be diagnosed years earlier Pancreatic cancer could be identified in patients up to three years earlier than current diagnoses, new research from the U.K. shows. Weight loss and increasing blood glucose levels are early indicators of pancreatic cancer and could lead to a more timely diagnosis, helping to improve survival rates. In the largest study of its kind, researchers […] November 1, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2022 First patient enrolled and dosed on expansion phase of cancer treatment trial The first patient in an expansion phase of a trial looking at cancer drug Modi-1 has been enrolled and dosed. Scancell Holdings plc, the developer of immunotherapies for the treatment of cancer and infectious disease made the announcement today (October 31). The expansion phase is part of the monotherapy arms of the phase 1 clinical […] October 31, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email